Cargando…

A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation

The development of specific antiviral compounds to SARS-CoV-2 is an urgent task. One of the obstacles for the antiviral development is the requirement of biocontainment because infectious SARS-CoV-2 must be handled in a biosafety level-3 laboratory. Replicon, a non-infectious self-replicative viral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotaki, Tomohiro, Xie, Xuping, Shi, Pei-Yong, Kameoka, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838314/ https://www.ncbi.nlm.nih.gov/pubmed/33500537 http://dx.doi.org/10.1038/s41598-021-82055-0

Ejemplares similares

Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities
por: Takazawa, Shunta, et al.
Publicado: (2023)

Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon
por: Nakamura, Akina, et al.
Publicado: (2022)

SARS-CoV-2 replicon for high-throughput antiviral screening
por: Zhang, Qiu-Yan, et al.
Publicado: (2021)

Reverse genetic systems of SARS-CoV-2 for antiviral research
por: Kurhade, Chaitanya, et al.
Publicado: (2023)

Inactivation of SARS-CoV-2 and influenza A virus by dry fogging hypochlorous acid solution and hydrogen peroxide solution
por: Urushidani, Masahiro, et al.
Publicado: (2022)

Development of A MERS-CoV Replicon Cell Line for Antiviral Screening
por: Chen, Jing, et al.
Publicado: (2021)

Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing
por: He, Xi, et al.
Publicado: (2021)

A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery
por: Jin, Yun-Yun, et al.
Publicado: (2021)

Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies
por: Nguyen, Hai Trong, et al.
Publicado: (2021)

Zika Virus Replicons for Drug Discovery
por: Xie, Xuping, et al.
Publicado: (2016)

Replication and single-cycle delivery of SARS-CoV-2 replicons
por: Ricardo-Lax, Inna, et al.
Publicado: (2021)

The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2
por: Bills, Cody, et al.
Publicado: (2023)

Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors
por: Luo, Yuewen, et al.
Publicado: (2021)

Nanopore sequencing of SARS-CoV-2: Comparison of short and long PCR-tiling amplicon protocols
por: Brejová, Broňa, et al.
Publicado: (2021)

Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation
por: Wang, Bei, et al.
Publicado: (2021)

A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2
por: Zhang, Yang, et al.
Publicado: (2021)

Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections
por: Zou, Jing, et al.
Publicado: (2022)

CRISPR/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures
por: Ophinni, Youdiil, et al.
Publicado: (2018)

Direct comparison of RT-ddPCR and targeted amplicon sequencing for SARS-CoV-2 mutation monitoring in wastewater
por: Lou, Esther G., et al.
Publicado: (2022)

High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery
por: Ge, Feng, et al.
Publicado: (2008)

Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening
por: Tanaka, Tomohisa, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
por: Muruato, Antonio, et al.
Publicado: (2021)

Evasion of Type I Interferon by SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2020)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Rapid and sensitive amplicon-based genome sequencing of SARS-CoV-2
por: Park, Changwoo, et al.
Publicado: (2022)

Japanese Encephalitis DNA Vaccines with Epitope Modification Reduce the Induction of Cross-Reactive Antibodies against Dengue Virus and Antibody-Dependent Enhancement of Dengue Virus Infection
por: Kotaki, Tomohiro, et al.
Publicado: (2022)

Correction for Zhou et al., “Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections”
por: Zou, Jing, et al.
Publicado: (2022)

A DNA-based non-infectious replicon system to study SARS-CoV-2 RNA synthesis
por: Feng, Xiaolong, et al.
Publicado: (2022)

Making sense of spike D614G in SARS-CoV-2 transmission
por: Shi, Aria C., et al.
Publicado: (2021)

Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes
por: Liu, Yang, et al.
Publicado: (2021)

Targeted amplicon sequencing of wastewater samples for detecting SARS-CoV-2 variants with high sensitivity and resolution
por: Kuroiwa, Miho, et al.
Publicado: (2023)

Humoral immunity for durable control of SARS-CoV-2 and its variants
por: Kotaki, Ryutaro, et al.
Publicado: (2023)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
por: Szurgot, Inga, et al.
Publicado: (2021)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin
por: Miller, Aaron L., et al.
Publicado: (2022)

An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif
por: Fang, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c2tqfqsl2jgbq2rg2o7l5hm7g3